These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22845044)

  • 1. Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system.
    Kapil RP; Cipriano A; Michels GH; Perrino P; O'Keefe SA; Shet MS; Colucci SV; Noveck RJ; Harris SC
    Clin Drug Investig; 2012 Sep; 32(9):583-92. PubMed ID: 22845044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects.
    Wang Y; Cipriano A; Munera C; Harris SC
    J Clin Pharmacol; 2016 Oct; 56(10):1263-71. PubMed ID: 26865472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
    Boinpally R; Gad N; Gupta S; Periclou A
    Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels.
    Kapil RP; Cipriano A; Friedman K; Michels G; Shet MS; Colucci SV; Apseloff G; Kitzmiller J; Harris SC
    J Pain Symptom Manage; 2013 Jul; 46(1):65-75. PubMed ID: 23026548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
    Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
    Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
    Harris SC; Morganroth J; Ripa SR; Thorn MD; Colucci S
    Postgrad Med; 2017 Jan; 129(1):69-80. PubMed ID: 27927048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
    Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
    J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
    Shoaf SE; Bricmont P; Mallikaarjun S
    Br J Clin Pharmacol; 2012 Apr; 73(4):579-87. PubMed ID: 21988334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
    Shaik MN; LaBadie RR; Rudin D; Levin WJ
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.
    Langdon G; Davis J; Layton G; Chong CL; Weissgerber G; Vourvahis M
    Br J Clin Pharmacol; 2012 May; 73(5):768-75. PubMed ID: 22040521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
    Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
    Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole greatly increases the exposure to oral buprenorphine.
    Fihlman M; Hemmilä T; Hagelberg NM; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1615-1622. PubMed ID: 30167757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
    Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
    Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
    Swart PJ; Krauwinkel WJ; Smulders RA; Smith NN
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):33-6. PubMed ID: 16867168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
    Steiner D; Munera C; Hale M; Ripa S; Landau C
    J Pain; 2011 Nov; 12(11):1163-73. PubMed ID: 21807566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.
    Pithavala YK; Tong W; Mount J; Rahavendran SV; Garrett M; Hee B; Selaru P; Sarapa N; Klamerus KJ
    Invest New Drugs; 2012 Feb; 30(1):273-81. PubMed ID: 20740300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.